title: Molecular determinants of local anesthetic action of beta-blocking drugs: Implications for therapeutic management of long QT syndrome variant 3.
abstract: The congenital long QT syndrome (LQTS) is a heritable arrhythmia in which mutations in genes coding for ion channels or ion channel associated proteins delay ventricular repolarization and place mutation carriers at risk for serious or fatal arrhythmias. Triggers and therapeutic management of LQTS arrhythmias have been shown to differ in a manner that depends strikingly on the gene that is mutated. Additionally, beta-blockers, effective in the management of LQT-1, have been thought to be potentially proarrhythmic in the treatment of LQT-3 because of concomitant slowing of heart rate that accompanies decreased adrenergic activity. Here we report that the beta-blocker propranolol interacts with wild type (WT) and LQT-3 mutant Na(+) channels in a manner that resembles the actions of local anesthetic drugs. We demonstrate that propranolol blocks Na(+) channels in a use-dependent manner; that propranolol efficacy is dependent on the inactivated state of the channel; that propranolol blocks late non-inactivating current more effectively than peak sodium current; and that mutation of the local anesthetic binding site greatly reduces the efficacy of propranolol block of peak and late Na(+) channel current. Furthermore our results indicate that this activity, like that of local anesthetic drugs, differs both with drug structure and the biophysical changes in Na(+) channel function caused by specific LQT-3 mutations.
authors.affiliation: Department of Pharmacology, College of Physicians and Surgeons, Columbia University, New York, NY 10032, USA.
authors.forename: John R
authors.initials: JR
authors.lastname: Bankston
authors.forename: Robert S
authors.initials: RS
authors.lastname: Kass
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000779:Anesthetics, Local / Q000494:pharmacology* / Q000627:therapeutic use; D002227:Carbazoles / Q000494:pharmacology / Q000627:therapeutic use; D000077261:Carvedilol; D002460:Cell Line; D004594:Electrophysiology; D006321:Heart / Q000187:drug effects; D006801:Humans; D008133:Long QT Syndrome / Q000188:drug therapy* / Q000378:metabolism*; D008790:Metoprolol / Q000494:pharmacology / Q000627:therapeutic use; D011412:Propanolamines / Q000494:pharmacology / Q000627:therapeutic use; D011433:Propranolol / Q000494:pharmacology / Q000627:therapeutic use; D015222:Sodium Channels / Q000378:metabolism*
chemical_list: D000319:Adrenergic beta-Antagonists; D000779:Anesthetics, Local; D002227:Carbazoles; D011412:Propanolamines; D015222:Sodium Channels; D000077261:Carvedilol; D011433:Propranolol; D008790:Metoprolol